You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Moodys
Dow
McKesson
Johnson and Johnson

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Human immunoglobulin g - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for human immunoglobulin g
Tradenames:5
Patents:45
Applicants:3
BLAs:5
Suppliers: see list3
Recent Clinical Trials: See clinical trials for human immunoglobulin g
Recent Clinical Trials for human immunoglobulin g

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Massimo GirardisPhase 3
Zhejiang Provincial Hospital of TCMEarly Phase 1
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEarly Phase 1

See all human immunoglobulin g clinical trials

Patent Text Search: US Patents for human immunoglobulin g

These patents were identified by searching patent claims

Supplementary Protection Certificates for human immunoglobulin g

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/045 United Kingdom   Start Trial PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526
5/1996 Austria   Start Trial PRODUCT NAME: REKOMBINANTES HUMANES FOLLIKELSTIMULIERENDES HORMON
2016000086 Germany   Start Trial PRODUCT NAME: ALBUMINFUSIONSPROTEINE AUFWEISEND FAKTOR IX FUSIONIERT MIT HUMANEM ALBUMIN; REGISTRATION NO/DATE: EU/1/16/1095 20160511
C/GB02/026 United Kingdom   Start Trial PRODUCT NAME: ANAKINRA (ALSO KNOWN AS HUMAN IL-1RA); REGISTERED: UK EU/1/02/203/001 20020308; UK EU/1/02/203/002 20020308; UK EU/1/02/203/003 20020308; UK EU/1/02/203/004 20020308
2016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
C/GB01/022 United Kingdom   Start Trial PRODUCT NAME: RECOMBINANT HUMAN LUTEINISING HORMONE; REGISTERED: UK EU/1/00/155/001-006 20001129
/2001 Austria   Start Trial PRODUCT NAME: RECOMBINANTES HUMANES OSTEOGENES PROTEIN-1 (OP 1); REGISTRATION NO/DATE: EU/1/01/179/001 20010517
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Medtronic
Baxter
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.